|
|
CBR's team of scientific researchers integrates biochemical analysis, protein chemistry and biological research to address key health and regulatory issues regarding biological therapeutics manufactured in Canada or elsewhere. Research expertise reflects ongoing HPFB priorities in areas such as protein analysis, glycobiology cell-based assays and virology, as well as government priorities in new fields such as stem cells, nanotechnology and neurobiology. The research is applied to blood and blood products, viral and bacterial vaccines, gene therapy products, tissues, organs and xenografts, monoclonal antibodies, hormones, enzymes, cytokines and many other therapeutic products derived from biotechnology. CBR draws on its own scientific expertise as well as on internal and external collaborations, using a strategic and multidisciplinary approach to research. Current thematic areas include subsequent entry biologics, vaccines and the immune response, development of more accurate and rapid assays, and rapid response to investigating adverse drug reactions.
|
